Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | CA12 | O43570 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | CA3 | P07451 | 3/20 | 0.50 |
| ▸ | CA4 | P22748 | 3/20 | 0.50 |
| ▸ | CA6 | P23280 | 3/20 | 0.50 |
| ▸ | CA5A | P35218 | 3/20 | 0.50 |
| ▸ | CA7 | P43166 | 3/20 | 0.50 |
| ▸ | CA9 | Q16790 | 3/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.50 |
| ▸ | CA5B | Q9Y2D0 | 3/20 | 0.50 |
| ▸ | AKR1B10 | O60218 | 3/20 | 0.50 |
| ▸ | AKR1B1 | P15121 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | DPP4 | P27487 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2324556 | 1.00 | NPSR1 (0.51) | NPSR1KDM4EHSD17B10MAPK1CA12 | |
| SCHEMBL16153884 | 0.87 | NPSR1 (0.51) | NPSR1KDM4EHSD17B10MAPK1CA12 | |
| SCHEMBL17365409 | 0.84 | KDM4E (0.55) | NPSR1KDM4EHSD17B10MAPK1CA12 | |
| SCHEMBL30744068 | 0.84 | KDM4E (0.55) | NPSR1KDM4EHSD17B10MAPK1CA12 | |
| SCHEMBL28483328 | 0.84 | KDM4E (0.55) | NPSR1KDM4EHSD17B10MAPK1CA12 | |
| SCHEMBL27841192 | 0.83 | TTR (0.56) | KDM4ECA12CA1CA2CA7 | |
| SCHEMBL29089142 | 0.81 | KDM4E (0.51) | NPSR1KDM4EHSD17B10MAPK1CA12 | |
| SCHEMBL2908080 | 0.80 | NPSR1 (0.59) | NPSR1KDM4EHSD17B10MAPK1CA12 | |
| SCHEMBL2908083 | 0.80 | NPSR1 (0.59) | NPSR1KDM4EHSD17B10MAPK1CA12 | |
| SCHEMBL20169657 | 0.79 | KDM4E (0.41) | KDM4EALDH1A1HPGDTHRBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9624520-B2 | Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues | NOVARTIS AG (CH) | 2017-04-18 | — | — | US | disclosed |
| US-20140302553-A1 | BIOSYNTHETICALLY GENERATED PYRROLINE-CARBOXY-LYSINE AND SITE SPECIFIC PROTEIN MODIFICATIONS VIA CHEMICAL DERIVATIZATION OF PYRROLINE-CARBOXY-LYSINE AND PYRROLYSINE RESIDUES | IRM LLC (BM) | 2014-10-09 | — | — | US | disclosed |
| US-8785151-B2 | Biosynthetically generated pyrroline-carboxy-lysine and site specific protein modifications via chemical derivatization of pyrroline-carboxy-lysine and pyrrolysine residues | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2014-07-22 | — | — | US | disclosed |
| EP-2356092-B1 | BIOSYNTHETICALLY GENERATED PYRROLINE-CARBOXY-LYSINE AND SITE SPECIFIC PROTEIN MODIFICATIONS VIA CHEMICAL DERIVATIZATION OF PYRROLINE-CARBOXY-LYSINE AND PYRROLYSINE RESIDUES | IRM LLC (BM) | 2014-04-16 | — | — | EP | disclosed |
| US-20110262963-A1 | BIOSYNTHETICALLY GENERATED PYRROLINE-CARBOXY-LYSINE AND SITE SPECIFIC PROTEIN MODIFICATIONS VIA CHEMICAL DERIVATIZATION OF PYRROLINE-CARBOXY-LYSINE AND PYRROLYSINE RESIDUES | NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) | 2011-10-27 | — | — | US | disclosed |
| EP-2356092-A1 | BIOSYNTHETICALLY GENERATED PYRROLINE-CARBOXY-LYSINE AND SITE SPECIFIC PROTEIN MODIFICATIONS VIA CHEMICAL DERIVATIZATION OF PYRROLINE-CARBOXY-LYSINE AND PYRROLYSINE RESIDUES | IRM LLC (BM) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010048582-A1 | BIOSYNTHETICALLY GENERATED PYRROLINE-CARBOXY-LYSINE AND SITE SPECIFIC PROTEIN MODIFICATIONS VIA CHEMICAL DERIVATIZATION OF PYRROLINE-CARBOXY-LYSINE AND PYRROLYSINE RESIDUES | IRM LLC (BM) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110262963-A1 | BIOSYNTHETICALLY GENERATED PYRROLINE-CARBOXY-LYSINE AND SITE SPECIFIC PROTEIN MODIFICATIONS VIA CHEMICAL DERIVATIZATION OF PYRROLINE-CARBOXY-LYSINE AND PYRROLYSINE RESIDUES | PTMS, PHYKPL, DNPEP | NPSR1 1438/4885KDM4E 754/4885HSD17B10 3575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.